Drug intelligence / Profile preview

Shu Mi Capsules

Development stage: Preclinical
Lead developer: Yantai Rongchang Pharmaceutical
Administration: Oral

Overview

Shu Mi Capsules is a traditional Chinese medicine (TCM) formulation developed by Rongchang Pharmaceutical (Zibo) Co., Ltd. for the treatment of constipation. It is currently undergoing clinical evaluation in China, including a randomized clinical study scheduled for 2026 at the Gansu Provincial Traditional Chinese Medicine Hospital. In these studies, it is being compared against other established TCM laxatives, such as Qi Huang Tong Mi Soft Capsules and Ma Ren Run Chang Soft Capsules. As a TCM product, it likely utilizes a combination of botanical extracts intended to promote gastrointestinal motility and alleviate symptoms of constipation, though its specific herbal composition has not been detailed in public clinical registries.

Brand names: Shu Mi Capsules
Other names: Shu Mi Jiao Nang

Beyond the preview

Go deeper on Shu Mi Capsules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shu Mi Capsules.

Explore the full profile